14th Annual Lynn Sage Breast Cancer Symposium
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
676 North St. Clair Street Suite 1200 Chicago, Illinois 60611
Chicago, Illinois
The optimal management of breast cancer continues to evolve based on new research findings. A multidisciplinary team of medical, surgical and radiation oncologists, pathologists, plastic surgeons and genetic counselors are routinely involved in treatment planning for breast cancer patients. With the emergence of new prevention strategies, women at high risk of developing breast cancer are now evaluated for medical therapies, surgical options and lifestyle changes that may reduce their risk of developing breast cancer. With new information about the molecular makeup of the tumor, treatment options are individualized. The 14th Annual Lynn Sage Breast Cancer Symposium provides a forum for presenting laboratory and clinical research and discussing the care of patients with breast cancer. Various case studies will be presented and discussed throughout the breast cancer symposium utilizing an electronic Audience Response System.
At the conclusion of this symposium participants should be able to:

    Determine the impact of co-morbidities on an elderly patients prognosis and appropriateness for systemic cancer therapy.

    Explain the impact of cancer therapy on sexual function and satisfaction.

    Realize the options and indications for neo-adjuvant therapy in locally advanced breast cancer.

    Summarize the challenges and available options in treating triple negative breast cancer.

    Identify new agents for overcoming endocrine resistance.

    Evaluate the role of partial breast irradiation and compare this option to standard of care.

    Review the treatment options for patient with ductal carcinoma in situ and how best to fit these treatment modalities to the appropriate individual.

    Explain and review the role of meta-analysis in clarifying the activity of adjuvant therapies for breast cancer.


Schedule of Presentations:

Thursday, October 4, 2012
08:00:00 Breakfast and Exhibits Virginia Kaklamani
09:00:00 Symposium Welcome Seema A. Khan
09:10:00 Session 1 | Supportive Oncology Lynn C Hartmann
09:15:00 Decision Tools in Elderly Patient Claudine Isaacs
09:45:00 Pathophysiology of Cancer-Related Bone Pain Patrick Mantyh
10:15:00 Chemotherapy-Induced Peripheral Neuropathy Nora Hansen
10:45:00 Integration of Early Palliative Care into Breast Cancer Care V. Craig Jordan
11:15:00 Questions and Answers
11:30:00 Lunch Break and Dessert with Exhibitors Kathleen I. Pritchard
12:55:00 Session 2 | Pathology for the Non-Pathologist Kalliopi Siziopikou
13:00:00 Clinical Trials Update – NSABP B-32 Thomas Julian
13:30:00 Pathologic Features and Molecular Characteristics of Familial Breast Cancer Kalliopi Siziopikou
14:00:00 Lobular Neoplasia: Differential Diagnosis and Therapeutic Implications Timothy Jacobs
14:30:00 Molecular Diagnostics in Breast Pathology Jennifer Hunt
15:00:00 Questions and Answers
15:15:00 Break
15:25:00 Session 3 | Challenging Clinical Cases William Gradishar
15:30:00 Challenging Clinical Case Studies Panelists:
15:35:00 Case 1: Young Women with BRCA1-Induced, Early Breast Cancer
15:35:00 Case2: Inflammatory Breast Cancer With Residual Inflammatory Changes After Chemo
17:00:00 Adjourn
17:30:00 Welcome Reception
Friday, October 5, 2012
07:00:00 Breakfast and Exhibits
07:55:00 Session 4 | Risk, Staging and Diagnosis Virginia Kaklamani
08:00:00 Imaging High Risk Women: Who, How, and How Often? Seema A. Khan
08:45:00 Benign Breast Disease and Risk: What’s New? Lynn C Hartmann
09:15:00 BRCA Testing in Women With and Without Cancer Claudine Isaacs
09:45:00 Break
10:15:00 Risk Management Strategies for BRCA Mutation Carriers Nora Hansen
10:45:00 Chemoprevention of Breast Cancer: Lessons Learned V. Craig Jordan
11:15:00 Questions and Answers
11:30:00 LYNN SAGE DISTINGUISHED LECTURER The Oxford Overview: Is It Still Relevant In 2012? Kathleen I. Pritchard
12:30:00 Lunch Break and Dessert with Exhibitors
13:40:00 Session 5 | Controversies in Practice Today William J. Gradishar
13:45:00 Follow-up after Treatment: What’s Needed, What’s Not? Ruth O’Regan
14:15:00 Can the Treatment of DCIS be Individualized? Lawrence Solin
14:45:00 Neoadjuvant Therapy Jennifer Hunt
15:15:00 Questions and Answers
15:30:00 Break
15:45:00 Current Status of Antiangiogenics Hope S. Rugo
16:15:00 What is an Adequate Margin in Breast Conserving Surgery? Jay Harris
16:45:00 Questions and Answers
17:00:00 Adjourn
Saturday, October 6, 2012
07:55:00 Session 6 | Unresolved Problems Seema A. Khan
08:00:00 Breakfast and Exhibits
09:00:00 Approaches to Triple Negative Breast Cancer Joyce O’Shaughnessy
09:30:00 Selecting the Right Genomic Assay William J. Gradishar
10:00:00 Optimizing Reconstructive Outcomes when PMRT is Necessary Babak Mehrara
10:30:00 Obesity, Inflammation and Breast Cancer Clifford Hudis
11:00:00 Questions and Answers
11:30:00 Lunch Break and Dessert with Exhibitors
12:55:00 Session 7 | Breast Cancer and the Elderly William Small Jr
13:00:00 Selecting Local Therapy in the Elderly Kevin Hughes
13:30:00 Radiation Alternatives in the Older Patient: Intraoperative, Short Course, PBI Alice Ho
14:00:00 Systemic Therapy Considerations Hyman B. Muss
14:30:00 New Agents fo Overcoming Endocrine Resistance José Baselga
15:00:00 Questions and Answers
15:15:00 Break
16:00:00 Multidisciplinary Tumor Board: Case Reviews and Audience Response Monica Morrow
17:15:00 Adjourn
Sunday, October 7, 2012
08:55:00 Session 8 | Managing the Axilla – What to do Now? Nora Hansen
09:00:00 MA20 – Should All Patients with Nodal Involvement Have Nodal RT? Lori J. Pierce
09:30:00 Z11 One Year Later: Issues and Implementation Monica Morrow
10:00:00 The Medical Oncologist and Nodes: Do We Still Care? Eric Winer
10:30:00 Panel Discussion and Questions
11:15:00 Questions and Answers
11:15:00 Adjourn
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.